NCT01587079 - Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

159

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

October 31, 2012

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

PT003

PT003 MDI administered as two puffs BID for 7 days

DRUG

PT001

PT001 MDI administered as two puffs BID for 7 days

DRUG

PT005

PT005 MDI administered as two puffs BID for 7 days

DRUG

Tiotropium inhalation powder

Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days

Trial Locations (19)

29303

Pearl Investigative Site, Spartanburg

32789

Pearl Investigative Site, Winter Park

33765

Pearl Investigative Site, Clearwater

97504

Pearl Investigative Site, Medford

Unknown

Pearl Investigative Site, Glendale

Pearl Investigative Site, Rancho Mirage

Pearl Investigative Site, Waterbury

Pearl Investigative Site, Clearwater

Pearl Investigative Site, Pensacola

Pearl Investigative Site, Lafayette

Pearl Investigative Site, North Dartmouth

Pearl Investigative Site, Fridley

Pearl Investigative Site, St Louis

Pearl Investigative Site, Summit

Pearl Investigative Site, Cincinnati

Pearl Investigative Site, Medford

Pearl Investigative Site, Rock Hill

Pearl Investigative Site, San Antonio

Pearl Investigative Site, Morgantown